文献速递中枢神经肿瘤放疗胸部肿瘤放疗

EGFR突变预测非小细胞肺癌脑转移患者立体定向放射外科治疗预后良好

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
PubMed 文献 · Radiother Oncol · 2017-10-27

该回顾性研究分析2008至2015年147例非小细胞肺癌脑转移患者共300个病灶,评估EGFR突变状态对立体定向放射外科(SRS)疗效的影响。结果显示EGFR突变患者影像学完全缓解率更高,SRS后新发脑转移中位时间显著延长(17 vs 10.5个月,p=0.02),多因素分析中EGFR突变独立预测更好的脑无进展生存(HR=0.55,p=0.048)。

要点

  • EGFR突变患者SRS后影像学完全缓解率更高。
  • 突变患者新发脑转移中位时间显著延长(17 vs 10.5个月,p=0.02)。
  • EGFR突变独立预测更好脑无进展生存(HR=0.55,p=0.048)。

核心结论

  • EGFR突变与非小细胞肺癌脑转移SRS后更高的完全缓解率、更长的远隔脑控制时间和更好的脑无进展生存相关。

研究设计与样本

  • 回顾性分析2008至2015年147例符合条件的非小细胞肺癌脑转移患者共300个病灶,接受 upfront 或挽救性SRS。

主要发现

  • 中位随访13.5个月,EGFR基因分型患者中79例(65%)为突变型,42例(35%)为野生型。
  • EGFR突变与更高的影像学完全缓解率相关。
  • 突变患者SRS后新发脑转移中位时间显著更长(17 vs 10.5个月,p=0.02),在辅助TKI治疗者中尤为明显(26.3 vs 15个月,p=0.01)。
  • 多因素分析中EGFR突变独立预测更好脑无进展生存(HR=0.55,p=0.048)。

临床怎么用

  • 对EGFR突变的选择性患者,SRS联合TKI可作为脑转移的有效治疗选择,脑控制良好且神经毒性小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The impact of epidermal growth factor receptor (EGFR) mutations on radiotherapy for brain metastases (BM) is undetermined. We evaluated the effects of EGFR mutation status on responses and outcomes in non-small cell lung cancer (NSCLC) patients with BM, treated with upfront or salvage stereotactic radiosurgery (SRS). METHODS AND MATERIALS: From 2008 to 2015, 147 eligible NSCLC patients with 300 lesions were retrospectively analyzed. Patterns of tyrosine kinase inhibitor (TKI) therapy were recorded. Radiographic response was assessed. Brain progression-free survival (BPFS) and overall survival were calculated and outcome prognostic factors were evaluated. RESULTS: Median follow-up time was 13.5 months. Of the EGFR-genotyped patients, 79 (65%) were EGFR mutants, and 42 (35%) were wild type. Presence of EGFR mutations was associated with higher radiographic complete response rates (CRR). Median time to develop new BM after SRS was significantly longer for mutant-EGFR patients (17 versus 10.5 months, p = 0.02), predominantly for those with adjuvant TKI therapy (26.3 versus 15 months, p = 0.01). EGFR mutations independently predicted better BPFS (HR = 0.55, p = 0.048) in multivariate analysis. CONCLUSIONS: In patients with NSCLC treated with SRS for BM, the presence of EGFR mutations is associated with a higher CRR, longer time for distant brain control, and better BPFS. The combination of SRS and TKI in selective patient group can be an effective treatment choice for BM with favorable brain control and little neurotoxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yang WC, Xiao F, Shih JY, et al. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2017. PMID: 29111173. doi:10.1016/j.radonc.2017.10.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。